
    
      This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study of the
      efficacy and safety of apremilast 20 mg twice a day (BID), apremilast 30 mg BID, and placebo
      in Japanese participants with moderate to severe plaque psoriasis.
    
  